Companies

Novartis AG ADR

NYSE: NVS
$161.50
▲ $0.40 (+0.25%) today
Markets open · 3:06pm ET

24/7 Wall St. View

NVS at a Glance

Price
24/7 target
$175.79
Street target
$154.65
Earnings
Q3 2026 EPS
$2.46
vs. $2.24 est.
+9.7%

NYSE: NVS

About Novartis

Novartis is a pure-play innovative medicines company that researches, develops, manufactures and sells prescription pharmaceuticals, operating as a single global segment. It focuses on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology. It also maintains a portfolio of established brands.

Its technology platforms span:
- Chemistry and biotherapeutics (established platforms)
- Gene & cell therapy, radioligand therapy and xRNA (emerging platforms prioritized for investment)

Key marketed products include:
- Oncology: Kisqali, Pluvicto, Scemblix, Jakavi, Tafinlar + Mekinist, Lutathera and Fabhalta
- Immunology: Cosentyx, Ilaris, Xolair and Rhapsido
- Neuroscience: Kesimpta, Zolgensma/Itvisma and Aimovig
- Cardiovascular-renal-metabolic: Entresto, Leqvio and Vanrafia

Its priority geographies are the US, China, Germany and Japan, and its medicines reach more than 300 million people.

Novartis is offsetting generic erosion of Entresto, Promacta and Tasigna with launches and bolt-on acquisitions. In 2026 these included Avidity Biosciences (RNA therapeutics for neuromuscular diseases), Myricx Pharma (ADCs), Pikavation and Excellergy. It has about 100 projects in clinical development. Updated

Latest Activity

Mad Money w/ Jim Cramer 10/27/26

  • Cramer rejects the AI all-clear despite Broadcom arranging $63 billion in financing for Anthropic compute
  • Meta's $25 billion equity raise was five times oversubscribed, but the $60 billion at-the-market program worries him
  • CoreWeave bonds reaching a 15% yield flagged as the sector's unresolved weak spot
  • Caller questions on Micron volatility and Revolution Medicines' pancreatic cancer drug

The bull case for data centers today rested on financing rather than profits, and Cramer wants to hear a customer say the chips are minting money before calling it clear. He expects Meta's at-the-market selling to weigh on the stock as supply hits at the wrong moments, with borrowing costs into a Fed decision the swing factor for everything levered to the buildout.

NVSNovartis
Regular session
$150.55
-3.54%open $156.08

A 3.54% slide to $150.55 wipes roughly $10 billion off a $286 billion pharma name that rarely moves this much in a single session. Defensive large-cap drugmakers trading like this is worth a look before the close.

NVS Coverage

10:48am ET
Investing

6 Health Care Dividend Stocks to Buy Hand Over Fist

While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the country ages;…

Lee Jackson

Frequently Asked Questions

What does Novartis do?

Novartis is a pure-play innovative medicines company that researches, develops, manufactures and sells prescription pharmaceuticals, operating as a single global segment. It focuses on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology.

What is the NVS stock price target?

24/7 Wall St.'s 12-month price target for NVS is $175.79, rated Buy. The Wall Street consensus target is $154.65. NVS price prediction →